Epizyme Inc. (NASDAQ:EPZM) shot up 7.8% on Friday . The stock traded as high as $10.62 and last traded at $10.60, with a volume of 264,065 shares trading hands. The stock had previously closed at $9.83.

Several research firms recently weighed in on EPZM. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, July 11th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Tuesday, May 10th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 target price on shares of Epizyme in a research note on Monday, June 20th. Finally, Mizuho reduced their target price on shares of Epizyme from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.11.

The firm’s market capitalization is $590.53 million. The company has a 50-day moving average price of $10.24 and a 200 day moving average price of $10.49.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.12. On average, equities analysts expect that Epizyme Inc. will post ($2.25) EPS for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Several hedge funds have recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the period. California Public Employees Retirement System purchased a new stake in shares of Epizyme during the fourth quarter worth $2,723,000. Finally, Jennison Associates increased its stake in shares of Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares during the period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.